Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum

Type 2 Diabetes Clinical Trial

Official title:

Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05219994
• Other study ID #: 2018486
• Status: Completed
• Phase: N/A
• Start date: September 9, 2020
• Est. completion date: May 10, 2023

Study information

• Verified date: July 2023
• Source: University of Missouri-Columbia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Our overall goal is to advance our understanding of the contribution of the carotid body chemoreceptors in glucose regulation and the development of type 2 diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: May 10, 2023
• Est. primary completion date: May 10, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• healthy,

• type 2 diabetes

• BMI 18-40 kg/m2,

• non-pregnant,

• non-breastfeeding,

• non-nicotine users.

Exclusion Criteria:

• cardiovascular disease including myocardial infarction, heart failure, coronary artery disease, stroke;

• renal or hepatic diseases;

• active cancer;

• autoimmune diseases;

• immunosuppressant therapy;

• excessive alcohol consumption (>14 drinks/week);

• current nicotine use;

• foot ulcers;

• diabetic neuropathy;

• medication directly influencing sympathetic nervous system activity

Related Conditions & MeSH terms

• Diabetes Mellitus
• Type 2 Diabetes

Intervention

Other:
• Hyperoxia Exposure
2 hours of hyperoxia exposure during OGTT
• Normoxia Exposure
2 hours of normoxia exposure during OGTT

Locations

Country	Name	City	State
United States	University of Missouri	Columbia	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
University of Missouri-Columbia

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glucose change in response to OGTT		2 hours post glucose ingestion
Primary	Insulin change in response to OGTT		2 hours post glucose ingestion